The first therapeutic vaccine against tuberculosis, which has been developed by doctors from the Germans Trias i Pujol Hospital in Badalona (Barcelona) and the Archivel Farma laboratory, and which presented positive immunological results in 96 patients, will be commercialized in 2015.

According to Pere-Joan Cardona, doctor of the aforementioned hospital, scientific director of Archivel Farma and discoverer of the vaccine, it has proven effective against Koch bacilli, both active and inactive, although until now the latter were not identified by the immune system, so you could not fight against them.

Researchers have proven that the vaccine is not toxic, and have achieved, with the same dose of 25 micrograms, a similar response in HIV positive and negative patients.

The AIDS virus is strongly associated with tuberculosis throughout the world, so Dr. Cardona and his team will include 1,300 people infected with HIV in phase III of the vaccine trial. Half of the patients will be given conventional treatment, while the others will receive a combination of the usual medications with the Ruti vaccine. If phase III confirms the results obtained with phase II, the vaccine will be available in 2015.

To complete the project, Archivel Farma needs 15 million euros to finance the last stages of the investigation and register the new drug.

The vaccine, which could be used both with people who have the infection in a latent state, and with patients who have already developed the disease, aims to eliminate the infection caused by the Koch bacillus, effectively stimulating the immune system that our body activates when detecting the bacilli.

The most relevant characteristic of the new vaccine is that it reduces the treatment time in those patients with latent infection, which would pass from the nine months that are currently needed to one month, and this would reduce the percentage of abandonment of the treatment.

Experts estimate that a third of the world's population is infected with tuberculosis, even if the disease has not developed. In addition, 10 percent of patients who are not treated will suffer a serious injury, which could even lead to death.